The Therapeutic Potential of Mesenchymal Stem Cell-derived Exosomes in Peritoneal Dysfunction

NCT07791667 | Not Yet Recruiting Phase 1

• 1 other identifier: 2025-KY-327-02
• Study Type: interventional
• Target: 12
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to learn if a single intraperitoneal infusion of mesenchymal stem cell-derived exosomes (MSC-Exos) is safe and tolerable in adults with peritoneal dialysis-related peritoneal failure. It will also explore whether MSC-Exos might improve how well the peritoneum works (ultrafiltration and solute transfer). The main questions it aims to answer are: What is the highest single dose of MSC-Exos that can be given safely without causing unacceptable side effects? (This helps find the maximum tolerated dose and the dose to use in future phase II studies.) What medical problems (adverse events) do participants experience after receiving MSC-Exos? Does MSC-Exos show any early signs of improving ultrafiltration volume and solute transport across the peritoneum? Researchers will test increasing doses of MSC-Exos in small groups of participants. Each participant will receive one dose of MSC-Exos added to their usual 1.5% glucose dialysis solution (2 litres), which is then left in the abdominal cavity for 8 hours. The study does not use a placebo; instead, different dose levels are tested one after another to find the safest and most promising dose. Participants will: Receive a single intraperitoneal infusion of MSC-Exos through their dialysis catheter Be monitored closely before the infusion； Attend follow-up visits at 24 hours, 72 hours, 2 weeks, and 4 weeks after the dose; Have blood and peritoneal effluent samples taken at each visit to check for safety ; Have their ultrafiltration volume and solute transport ability measured at baseline and 4 weeks after the dose to see if any changes occur. All participants will be closely observed for any side effects. The results will help decide whether further studies are warranted.

Conditions

Peritoneal Dysfunction

Outcome Measures

Primary Outcomes (2)

• Incidence of Dose-Limiting Toxicities (DLTs)

  Number of participants with MSC-Exos-related DLTs, defined as grade ≥3 local peritoneal reactions (abdominal pain / signs of peritonitis) or systemic allergic reactions assessed by CTCAE v5.0. Local reactions will be objectively supported by peritoneal effluent white blood cell count and polymorphonuclear (PMN) cell percentage.

  Within 72 hours post-administration

• Incidence of Serious Adverse Events (SAEs)

  Number of participants experiencing SAEs during the entire study period. Safety monitoring includes serial assessments of complete blood count, C-reactive protein (CRP), and liver/kidney function tests (ALT, AST, creatinine, BUN).

  Up to 4 weeks post-administration

Secondary Outcomes (4)

• Change in 4-hour Ultrafiltration Volume

  Baseline and Week 4

• Change in 4-hour D/Pcr Ratio

  Baseline and Week 4

• Change in 1-hour Sodium Dip

  Baseline and Week 4

• Change in Sodium Sieve

  Baseline and Week 4

Study Arms (3)

Dose Level 1 (5×10⁹ particles)

EXPERIMENTAL

Biological: MSC-Exos

Dose Level 2 (2.5×10¹⁰ particles)

EXPERIMENTAL

Biological: MSC-Exos

Dose Level 3 (1×10¹¹ particles)

EXPERIMENTAL

Biological: MSC-Exos

Interventions

MSC-Exos BIOLOGICAL

MSC-Exos will be added to 2 L of 1.5% glucose peritoneal dialysis fluid, which will be administered via intraperitoneal infusion and retained for 8 hours.

Dose Level 1 (5×10⁹ particles); Dose Level 2 (2.5×10¹⁰ particles); Dose Level 3 (1×10¹¹ particles)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who have been on continuous peritoneal dialysis for more than 1 year.
• Age ≥ 18 years.
• Patients meeting at least one of the following criteria for peritoneal ultrafiltration insufficiency:
• Standard PET-confirmed ultrafiltration failure: 4-hour ultrafiltration volume \< 400 mL using 4.25% glucose dialysate, or \< 100 mL using 2.5% glucose dialysate; ② 1-hour sodium dip \< 5 mmol/L and/or 1-hour sodium sieve ratio ≤ 0.03 using 4.25% glucose dialysate; ③ Inability to maintain fluid balance, as evidenced by persistent edema/heart failure symptoms, NT-proBNP \>11215.2 ng/L, or bioimpedance spectroscopy-assessed overhydration (OH) \>2 L (after excluding non-peritoneal causes).

You may not qualify if:

• Patients with acute renal failure or chronic renal failure who can be temporarily weaned from dialysis.
• Patients with malignant tumors, active infections, or severe malnutrition.
• Patients with severe hepatic failure or cirrhosis.
• Patients with severe cardiovascular disease, severe heart failure (NYHA Class IV or higher), or active systemic diseases.
• Patients with peritonitis within the past 3 months or currently experiencing peritonitis.
• Patients with encapsulating peritoneal sclerosis (EPS).
• Patients with peritoneal dialysis catheter dysfunction.
• Planned or ongoing pregnancy.
• Simultaneous participation in another interventional clinical trial or drug study.

Sponsors & Collaborators

• Zhujiang Hospital: lead

Central Study Contacts

Xun T Chief physicians

CONTACT

+86 20 6278 2305; 1847672118@qq.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief physicians

Study Record Dates

• First Submitted: August 11, 2026
• First Posted: August 28, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): August 1, 2027
• Last Updated: August 28, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share